The test is aimed at patients who may be prescribed opioids before surgeries. SOLVD Health and the FDA have stressed that the ...
A new additional drug in the fight against the opioid overdose crisis has slowly been making its way across the country and ...
In a letter to the agency, a group of experts called on the commissioner to revoke its approval, saying the test doesn't work ...
Researchers say a test meant to measure risk for opioid use disorder may cause harm. Their arguments are part of a larger ...
A test to gauge if it's safe to prescribe a patient an addictive opioid may have been approved too soon by the U.S. Food and ...
“Unfortunately, the test that the FDA just approved doesn't work. ... It's really no better than a coin flip when it comes to ...
“The harmful consequences of an invalid genetic test for [opioid use disorder] are clear ... it was reviewing the letters and that the FDA’s approval “represents a significant step ...
A group of public health experts and scientists is calling on the Food and Drug Administration to rescind its controversial approval of a DNA test that promises to predict genetic risk of opioid ...
The major risks associated with AvertD are false-negative and false-positive results, the FDA said. Before the agency ...
The test, called AvertD, was approved by the FDA in December. It detects a handful of genetic markers that the manufacturer, California-based SOLVD Health, claims are associated with opioid use ...
Physicians said the test is based “on old genetic studies that have largely been abandoned” and could exacerbate the opioid crisis.
The test, called AvertD, was approved by the FDA in December. It detects a handful of genetic markers that the manufacturer, California-based SOLVD Health, claims are associated with opioid use ...